
Taku Kobayashi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3388404/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ulcerative colitis. Nature Reviews Disease Primers, 2020, 6, 74.	18.1	678
2	Unique CD14+ intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-γ axis. Journal of Clinical Investigation, 2008, 118, 2269-80.	3.9	559
3	IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut, 2008, 57, 1682-1689.	6.1	470
4	Evidence-based clinical practice guidelines for inflammatory bowel disease. Journal of Gastroenterology, 2018, 53, 305-353.	2.3	427
5	Th17 plasticity and its relevance to inflammatory bowel disease. Journal of Autoimmunity, 2018, 87, 38-49.	3.0	214
6	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. Journal of Gastroenterology, 2021, 56, 489-526.	2.3	202
7	Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology, 2020, 158, 562-572.e12.	0.6	173
8	Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflammatory Bowel Diseases, 2012, 18, 2169-2179.	0.9	161
9	Dietary Histidine Ameliorates Murine Colitis by Inhibition of Proinflammatory Cytokine Production From Macrophages. Gastroenterology, 2009, 136, 564-574.e2.	0.6	139
10	Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. Gastroenterology, 2018, 154, 935-947.	0.6	139
11	Monocyte Chemoattractant Protein-1 Contributes to Gut Homeostasis and Intestinal Inflammation by Composition of IL-10–Producing Regulatory Macrophage Subset. Journal of Immunology, 2010, 184, 2671-2676.	0.4	128
12	An Anti-Inflammatory Role for Carbon Monoxide and Heme Oxygenase-1 in Chronic Th2-Mediated Murine Colitis. Journal of Immunology, 2011, 186, 5506-5513.	0.4	124
13	Human CD14+ Macrophages in Intestinal Lamina Propria Exhibit Potent Antigen-Presenting Ability. Journal of Immunology, 2009, 183, 1724-1731.	0.4	108
14	TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflammatory Bowel Diseases, 2010, 16, 568-575.	0.9	105
15	Carbon Monoxide and Heme Oxygenase-1 Prevent Intestinal Inflammation in Mice by Promoting Bacterial Clearance. Gastroenterology, 2013, 144, 789-798.	0.6	102
16	NFIL3 Is a Regulator of IL-12 p40 in Macrophages and Mucosal Immunity. Journal of Immunology, 2011, 186, 4649-4655.	0.4	101
17	First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis. Journal of Gastroenterology, 2016, 51, 241-251.	2.3	93
18	NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. Journal of Gastroenterology, 2018, 53, 1065-1078.	2.3	86

#	Article	IF	CITATIONS
19	Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ. Gastroenterology, 2010, 139, 1642-1653.e6.	0.6	78
20	Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. The Lancet Gastroenterology and Hepatology, 2020, 5, 393-405.	3.7	78
21	Lamina Propria c-kit+ Immune Precursors Reside in Human Adult Intestine and Differentiate Into Natural Killer Cells. Gastroenterology, 2007, 133, 559-573.	0.6	77
22	Exclusive increase of CX3CR1+CD28â^'CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. Inflammatory Bowel Diseases, 2007, 13, 837-846.	0.9	75
23	Cutting Edge: IFN-Î ³ Is a Negative Regulator of IL-23 in Murine Macrophages and Experimental Colitis. Journal of Immunology, 2010, 184, 4069-4073.	0.4	72
24	IL-10 Regulates <i>Il12b</i> Expression via Histone Deacetylation: Implications for Intestinal Macrophage Homeostasis. Journal of Immunology, 2012, 189, 1792-1799.	0.4	68
25	Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. Journal of Crohn's and Colitis, 2022, 16, 27-38.	0.6	66
26	Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa. Journal of Crohn's and Colitis, 2018, 12, 1288-1294.	0.6	58
27	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. The Lancet Gastroenterology and Hepatology, 2022, 7, 171-185.	3.7	57
28	Correlation between endocytoscopy and conventional histopathology in microstructural features of ulcerative colitis. Journal of Gastroenterology, 2011, 46, 1197-1202.	2.3	56
29	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 857-873.	8.2	56
30	Innate PI3K p110δ Regulates Th1/Th17 Development and Microbiota-Dependent Colitis. Journal of Immunology, 2014, 192, 3958-3968.	0.4	53
31	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflammatory Intestinal Diseases, 2019, 4, 79-96.	0.8	53
32	A Cell Permeable Peptide Inhibitor of NFAT Inhibits Macrophage Cytokine Expression and Ameliorates Experimental Colitis. PLoS ONE, 2012, 7, e34172.	1.1	50
33	Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2020, 51, 1373-1383.	1.9	50
34	A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice. Journal of Crohn's and Colitis, 2014, 8, 981-991.	0.6	49
35	Lipocalin 2 prevents intestinal inflammation by enhancing phagocytic bacterial clearance in macrophages. Scientific Reports, 2016, 6, 35014.	1.6	49
36	Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. Gastroenterology, 2022, 162, 482-494.	0.6	46

#	Article	IF	CITATIONS
37	NFIL3-Deficient Mice Develop Microbiota-Dependent, IL-12/23–Driven Spontaneous Colitis. Journal of Immunology, 2014, 192, 1918-1927.	0.4	41
38	Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. Journal of Gastroenterology, 2020, 55, 679-700.	2.3	39
39	Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. Journal of Gastroenterology, 2010, 45, 1129-1137.	2.3	38
40	Endocytoscopy can be used to assess histological healing in ulcerative colitis. Endoscopy, 2017, 49, 560-563.	1.0	38
41	Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 908-921.e6.	2.4	38
42	AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Gastroenterology and Hepatology, 2022, 7, 648-657.	3.7	38
43	Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. Journal of Crohn's and Colitis, 2021, 15, 1130-1141.	0.6	37
44	Involvement of herbal medicine as a cause of mesenteric phlebosclerosis: results from a large-scale nationwide survey. Journal of Gastroenterology, 2017, 52, 308-314.	2.3	35
45	Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. Journal of Gastroenterology, 2021, 56, 560-569.	2.3	34
46	Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 429-437.	3.7	34
47	Lectin-based Immunoassay for Aberrant IgG Glycosylation as the Biomarker for Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, 321-331.	0.9	33
48	Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. Journal of Gastroenterology, 2010, 45, 936-943.	2.3	32
49	Inducible colitis-associated glycome capable of stimulating the proliferation of memory CD4+ T cells. Journal of Experimental Medicine, 2012, 209, 2383-2394.	4.2	32
50	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterology Journal, 2021, 9, 451-460.	1.6	31
51	The dietary practices and beliefs of people living with inactive ulcerative colitis. European Journal of Gastroenterology and Hepatology, 2021, 33, 372-379.	0.8	30
52	Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1102-1111.e5.	2.4	29
53	Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. Inflammatory Intestinal Diseases, 2020, 5, 27-35.	0.8	29
54	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. The Lancet Gastroenterology and Hepatology, 2021, 6, 482-497.	3.7	28

#	Article	IF	CITATIONS
55	In Vitro and In Vivo Evaluation of a Water-in-Oil Microemulsion System for Enhanced Peptide Intestinal Delivery. AAPS Journal, 2013, 15, 288-298.	2.2	27
56	Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. Journal of Crohn's and Colitis, 2020, 14, 617-623.	0.6	26
57	Modified bowel preparation regimen for use in secondâ€generation colon capsule endoscopy in patients with ulcerative colitis. Digestive Endoscopy, 2014, 26, 665-672.	1.3	24
58	Longâ€ŧerm retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1031-1038.	1.4	24
59	Monozygotic twins concordant for intestinal Behçet's disease. Journal of Gastroenterology, 2005, 40, 421-425.	2.3	23
60	Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. Journal of Gastroenterology, 2020, 55, 169-180.	2.3	23
61	Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns? Journal of the Anus, Rectum and Colon, 2020, 4, 1-13.	0.4	21
62	Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. Digestive Diseases and Sciences, 2021, 66, 577-586.	1.1	21
63	Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis—Capsule Scoring of Ulcerative Colitis. Inflammatory Bowel Diseases, 2018, 24, 2641-2647.	0.9	19
64	Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. Inflammatory Bowel Diseases, 2008, 14, 1483-1490.	0.9	18
65	Characterization of an Interferon-stimulated Response Element (ISRE) in the Il23a Promoter. Journal of Biological Chemistry, 2011, 286, 1174-1180.	1.6	16
66	Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroidâ€free elderly patients. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1485-1491.	1.4	16
67	A Simple 1-Day Colon Capsule Endoscopy Procedure Demonstrated to be a Highly Acceptable Monitoring Tool for Ulcerative Colitis. Inflammatory Bowel Diseases, 2018, 24, 2404-2412.	0.9	16
68	Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLoS ONE, 2017, 12, e0185131.	1.1	16
69	In vivo visualization of trophozoites in patients with amoebic colitis by using a newly developed endocytoscope. Gastrointestinal Endoscopy, 2010, 72, 643-646.	0.5	15
70	Real-world Experience of Anti–tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease. Inflammatory Bowel Diseases, 2017, 23, 2245-2251.	0.9	15
71	Phosphoinositide 3-Kinase P110Î^-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation. Cells, 2019, 8, 1121.	1.8	15
72	Intestinal cancer in patients with Crohn's disease: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 329-336.	1.4	15

#	Article	IF	CITATIONS
73	Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 225-232.	1.4	14
74	Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 21-31.	0.9	14
75	Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intestinal Research, 2019, 17, 504-515.	1.0	14
76	A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1Âyear after leukocytapheresis. Journal of Gastroenterology, 2018, 53, 387-396.	2.3	13
77	Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial. Journal of Gastroenterology, 2021, 56, 147-157.	2.3	13
78	Capsule endoscopy in inflammatory bowel disease: when and how. Intestinal Research, 2020, 18, 265-274.	1.0	13
79	A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohn's disease. Journal of Gastroenterology, 2020, 55, 615-626.	2.3	12
80	Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intestinal Research, 2018, 16, 609-618.	1.0	12
81	Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. Intestinal Research, 2021, 19, 448-460.	1.0	11
82	Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 943-950.	1.4	10
83	Risk Factors for Mortality in <i>Pneumocystis jirovecii</i> Pneumonia in Patients with Inflammatory Bowel Disease. Inflammatory Intestinal Diseases, 2018, 3, 167-172.	0.8	9
84	Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. PLoS ONE, 2019, 14, e0212404.	1.1	9
85	Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. Intestinal Research, 2023, 21, 110-125.	1.0	9
86	Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. Inflammatory Intestinal Diseases, 2018, 3, 25-31.	0.8	8
87	Safety and efficacy of the endoscopic delivery of capsule endoscopes in adult and pediatric patients: Multicenter Japanese study (AdvanCEâ€J study). Digestive Endoscopy, 2022, 34, 543-552.	1.3	8
88	Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. Intestinal Research, 2019, 17, 87-93.	1.0	8
89	Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. Intestinal Research, 2018, 16, 168.	1.0	8
90	Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). Journal of Gastroenterology, 2022, 57, 174-184.	2.3	8

#	Article	IF	CITATIONS
91	Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2022, 55, 1320-1329.	1.9	8
92	Lower effectiveness of intravenous steroid treatment for moderateâ€ŧoâ€severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2022, 55, 1569-1580.	1.9	8
93	Does antiâ€ŧumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 864-872.	1.4	7
94	Certolizumab pegol for induction of remission in Crohn's disease. The Cochrane Library, 2019, 2019, CD012893.	1.5	6
95	Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn's Disease. Inflammatory Intestinal Diseases, 2020, 5, 78-83.	0.8	6
96	OUP accepted manuscript. Journal of Crohn's and Colitis, 2021, , .	0.6	6
97	Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1744-1753.	1.4	5
98	A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan. Journal of Gastroenterology, 2021, 56, 1062-1079.	2.3	5
99	Development of algorithms for identifying patients with Crohn's disease in the Japanese health insurance claims database. PLoS ONE, 2021, 16, e0258537.	1.1	5
100	Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease. Inflammatory Intestinal Diseases, 2018, 3, 1-10.	0.8	4
101	Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. BMJ Open, 2019, 9, e024222.	0.8	4
102	Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine Sâ€methyltransferase inhibition. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2116-2124.	1.4	4
103	Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. Inflammatory Bowel Diseases, 2022, 28, 200-207.	0.9	4
104	Validation of a claimsâ€based algorithm to identify cases of ulcerative colitis in Japan. Journal of Gastroenterology and Hepatology (Australia), 2021, , .	1.4	4
105	Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases. Digestion, 2022, 103, 169-173.	1.2	4
106	Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation. Journal of Gastroenterology, 2021, 56, 999-1007.	2.3	3
107	Certolizumab pegol for maintenance of medically induced remission in Crohn'sÂdisease. The Cochrane Library, 2022, 2022, .	1.5	3
108	Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis—one more arrow in the quiver of nonâ€invasive diagnostics. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 403-403.	1.9	2

#	Article	IF	CITATIONS
109	Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. Intestinal Research, 2019, 17, 218-226.	1.0	2
110	Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. Inflammatory Intestinal Diseases, 2021, 6, 186-198.	0.8	2
111	Nfil3 is a Regulator of IL-12 P40 in Macrophages and Mucosal Immunity. Gastroenterology, 2011, 140, S-109-S-110.	0.6	1
112	Which makes patients happier, surgery or anti-TNF therapy?. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 272-273.	8.2	1
113	Treatment Options after Anti-TNF Failure. Frontiers of Gastrointestinal Research, 0, , 229-233.	0.1	1
114	First Trough Level of Infliximab at Week 2 Predicts Future Outcomes of Induction Therapy in Ulcerative Colitis: A Post-hoc Analysis of a Multicenter Prospective Randomized Controlled Trial. American Journal of Gastroenterology, 2015, 110, S787.	0.2	1
115	Effects of CYP3A5 Genotype on Efficacy and Safety of Tacrolimus in Refractory Ulcerative Colitis: An Experience From a Tertiary Referral Center in Japan. American Journal of Gastroenterology, 2015, 110, S820.	0.2	1
116	Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab. Intestinal Research, 2017, 15, 535.	1.0	1
117	Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis—an accurate early predictor of response to treatment. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1204-1205.	1.9	1
118	Editorial: is olderâ€onset ulcerative colitis more severe or less aggressively managed? Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1352-1353.	1.9	1
119	Epigenetic regulation of IL-12 p40 by IL-10 in intestinal immunity. Inflammatory Bowel Diseases, 2011, 17, S11.	0.9	0
120	A case of gastric mucosal prolapse polyp that was difficult to differentiate from duodenal submucosal tumor. Progress of Digestive Endoscopy, 2016, 88, 106-107.	0.0	0
121	Endoscopic Indices for Ulcerative Colitis. , 2018, , 163-172.		0
122	Mo1669 NATIONWIDE MULTICENTER PROSPECTIVE STUDY ON USEFULNESS, SAFETY, AND ACCEPTABILITY OF COLON CAPSULE ENDOSCOPY IN JAPAN. Gastrointestinal Endoscopy, 2019, 89, AB513-AB514.	0.5	0
123	P078 CAPSULE SCORING OF ULCERATIVE COLITIS (CSUC) IS USEFUL FOR MONITORING INACTIVE ULCERATIVE COLITIS. Inflammatory Bowel Diseases, 2019, 25, S37-S37.	0.9	0
124	Stopping Anti-TNF in CD Remitters: Cons. Inflammatory Intestinal Diseases, 2022, 7, 1-5.	0.8	0
125	Stringent criteria for withdrawal of biologics in ulcerative colitis – Authors' reply. The Lancet Gastroenterology and Hepatology, 2021, 6, 688.	3.7	0
126	Endoscopic evaluation after surgery in inflammatory bowel disease – Authors' reply. The Lancet Gastroenterology and Hepatology, 2021, 6, 691-692.	3.7	0

#	Article	IF	CITATIONS
127	Short- and Long-term Efficacy of Intravenous Cyclosporine in Severe Ulcerative Colitis. American Journal of Gastroenterology, 2009, 104, S474.	0.2	0
128	Changes in endoscopic findings in a case of primary gastric amyloidosis. Progress of Digestive Endoscopy, 2014, 84, 88-89.	0.0	0
129	Usefulness of Fecal Calprotetin in Detecting the Early Response to Induction Therapy in Ulcerative Colitis. American Journal of Gastroenterology, 2016, 111, S330.	0.2	0
130	Usefulness of colestimide for diarrhea in postoperative Crohn's disease. JGH Open, 0, , .	0.7	0